Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:32:00 EDT Thu 26 Jun 2025
Enter Symbol
or Name
USA
CA



Q:CPIX - CUMBERLAND PHARMACEUTICALS INC - https://www.cumberlandpharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CPIX - Q0.12.68·2.930.12.55-0.75-22.7192.65249173.39  3.4622  2.51417.25  1.0419:36:53Jun 2315 min RT 2¢

Recent Trades - Last 10 of 917
Time ETExPriceChangeVolume
19:36:53Q2.6985-0.601524
18:54:22Q2.65-0.651,000
18:54:14Q2.65-0.65200
18:09:44Q2.6494-0.650615
18:01:25Q2.6598-0.640299
17:59:33Q2.6596-0.64041
17:13:55Q2.66-0.6415
17:11:23Q2.66-0.643
16:45:12Q2.61-0.69551
16:45:12Q2.6099-0.6901551

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-23 09:05U:CPIXNews ReleaseCumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
2025-05-27 16:05U:CPIXNews ReleaseNEW STUDY FINDS CALDOLOR(TM) SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS
2025-05-13 16:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
2025-05-06 16:05U:CPIXNews ReleaseCumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025
2025-04-29 16:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE
2025-03-19 16:05U:CPIXNews ReleaseFIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
2025-03-04 16:05U:CPIXNews ReleaseCumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
2025-02-25 16:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
2025-02-18 07:30U:CPIXNews ReleaseVIBATIV(TM) RECEIVES MARKETING APPROVAL IN CHINA
2025-02-04 07:30U:CPIXNews ReleaseCumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
2024-12-09 16:05U:CPIXNews ReleaseFDA APPROVES ACETADOTE(TM) sNDA
2024-11-07 16:05U:CPIXNews ReleaseCumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
2024-11-06 17:21U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
2024-11-05 16:05U:CPIXNews ReleaseNew Study Compares Caldolor(TM) (ibuprofen injection) to ketorolac
2024-10-31 16:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS
2024-08-06 16:05U:CPIXNews ReleaseCumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024
2024-07-30 16:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS